GlassScriptPhysician profile
Daria C Yanez
NPI 1790754786
$2,302.65
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $263 · 2021: $605 · 2022: $588 · 2023: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.95 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Exeltis, USA INC. | $209.90 | 2019-2023 | Slynd |
| Therapeuticsmd, INC. | $209.31 | 2019-2022 | |
| Evofem Biosciences, INC. | $175.63 | 2020-2023 | Phexxi |
| Mayne Pharma Commercial LLC | $132.68 | 2021-2023 | |
| Mylan Pharmaceuticals INC. | $113.56 | 2020-2022 | |
| Agile Therapeutics, INC. | $91.77 | 2021-2022 | |
| Coopersurgical, INC. | $84.17 | 2019-2022 | |
| Avion Pharmaceuticals | $82.24 | 2019-2022 | |
| Organon LLC | $81.68 | 2022-2023 | Nexplanon |
| Myovant Sciences INC. | $70.36 | 2021-2022 | |
| Amgen INC. | $66.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.67 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.57 | 2022 | |
| Astellas Pharma US INC | $44.37 | 2022-2023 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $36.26 | 2021-2022 | |
| Dysis Medical, INC. | $32.34 | 2019-2022 | |
| Allergan, INC. | $28.99 | 2019 | |
| Roche Diagnostics Corporation | $24.76 | 2020 | |
| Daiichi Sankyo INC. | $23.27 | 2023 | Injectafer |
| Millicent US INC | $22.01 | 2020 | |
| Baxter Healthcare | $20.71 | 2019 | |
| Sumitomo Pharma America, INC. | $18.86 | 2023 | Myfembree |
| Pfizer INC. | $17.12 | 2023 | |
| Vertical Pharmaceuticals, LLC | $16.90 | 2019 | |
| Covidien LP | $15.41 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.97 | 2019 | |
| Minerva Surgical, INC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daria Yanez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.